Search research articles
Contact Us
Filters
Showing results (91-100 of 237) with videos related to
Page
of 24
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 1, 2026
Conflicts of interest and interpretive authority in oncology
Saroj Niraula, Samuel X Stevens, Tito Fojo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 8, 2013
Cancer drugs in the United States: Justum Pretium--the just price
Hagop M Kantarjian, Tito Fojo, Michael Mathisen, et al.
Cancer Biology & Therapy
|
August 13, 2002
Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death
Mikhail V Blagosklonny, Robert Robey, M Saeed Sheikh, et al.
Cancer Research
|
April 17, 2004
A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins
Wilfred D Stein, Thomas Litman, Tito Fojo, et al.
International Journal of Cancer
|
October 30, 2004
Differential expression of cell adhesion genes: implications for drug resistance
Wilfred D Stein, Thomas Litman, Tito Fojo, et al.
JAMA Oncology
|
July 17, 2015
Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis
Irfan Jawed, Julia Wilkerson, Vinay Prasad, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
March 11, 2005
Radiofrequency ablation for tumor-related massive hematuria
Ziv Neeman, Shawn Sarin, Jonathan Coleman, et al.
The Journal of Biological Chemistry
|
September 8, 2006
Characterization of gene rearrangements leading to activation of MDR-1
Lyn M Huff, Jong-Seok Lee, Robert W Robey, et al.
Cancer Research
|
July 1, 2010
Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells
Lyn M Huff, Dan L Sackett, Marianne S Poruchynsky, et al.
Cancer Journal (Sudbury, Mass.)
|
October 15, 2009
Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development
Tatiana Vidaurre, Julia Wilkerson, Richard Simon, et al.
Page
of 24
Search research articles
Search
Showing results (91-100 of 237) with videos related to
Sort By:
Page
of 24
European Journal of Cancer (Oxford, England : 1990)
|
June 1, 2026
Conflicts of interest and interpretive authority in oncology
Saroj Niraula, Samuel X Stevens, Tito Fojo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 8, 2013
Cancer drugs in the United States: Justum Pretium--the just price
Hagop M Kantarjian, Tito Fojo, Michael Mathisen, et al.
Cancer Biology & Therapy
|
August 13, 2002
Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death
Mikhail V Blagosklonny, Robert Robey, M Saeed Sheikh, et al.
Cancer Research
|
April 17, 2004
A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins
Wilfred D Stein, Thomas Litman, Tito Fojo, et al.
International Journal of Cancer
|
October 30, 2004
Differential expression of cell adhesion genes: implications for drug resistance
Wilfred D Stein, Thomas Litman, Tito Fojo, et al.
JAMA Oncology
|
July 17, 2015
Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis
Irfan Jawed, Julia Wilkerson, Vinay Prasad, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
March 11, 2005
Radiofrequency ablation for tumor-related massive hematuria
Ziv Neeman, Shawn Sarin, Jonathan Coleman, et al.
The Journal of Biological Chemistry
|
September 8, 2006
Characterization of gene rearrangements leading to activation of MDR-1
Lyn M Huff, Jong-Seok Lee, Robert W Robey, et al.
Cancer Research
|
July 1, 2010
Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells
Lyn M Huff, Dan L Sackett, Marianne S Poruchynsky, et al.
Cancer Journal (Sudbury, Mass.)
|
October 15, 2009
Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development
Tatiana Vidaurre, Julia Wilkerson, Richard Simon, et al.
Page
of 24